KSAT 12: Lymphedema Treatment Act will cover what health insurance doesn’t
February 2, 2023
Anton Fries, MD, PhD, chief, Division of Plastic and Reconstructive Surgery, was interviewed for this news segment. Watch Now
Category
February 2, 2023
Anton Fries, MD, PhD, chief, Division of Plastic and Reconstructive Surgery, was interviewed for this news segment. Watch Now
January 27, 2023
By Arash Salardini, MD, Neurology, Glenn Biggs Institute The brain is among the most complex organs in the human body. As the body’s command center, it controls our memories, emotions, thoughts, movements, vision, motor skills, the processes that regulate our bodies and the attributes that make each one of us unique. Given its complex job, […]
January 26, 2023
For some men, preparing to watch their favorite college basketball teams duke it out during March Madness includes a comfortable chair, big screen TV, an ice pack and a vasectomy. “It’s the perfect time to relax at home and have something to do while you are recovering. There aren’t many sporting events like it […]
January 20, 2023
By Bradley Tragord, PT, DPT, DSc, associate professor, Department of Physical Therapy People who are physically active, tend to live longer and healthier lives. Individuals with risk factors like high blood pressure, diabetes or even a smoking habit, can benefit from incorporating physical activity into their daily routine. The U.S. Department of Health and Human […]
January 17, 2023
By Christiane Meireles, PhD, RD, LD, registered dietitian, clinical assistant professor In the midst of COVID-19, the flu and respiratory syncytial virus, or RSV, it’s natural to think about how to boost your immune system. Making healthy choices and changing lifestyle habits can support a healthy immune system. Increasing plant-based foods which are naturally nutrient-rich, among […]
January 11, 2023
Statement from the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases at UT Health San Antonio about a timely topic in the news: The U.S. Food and Drug Administration on Friday, Jan. 6, 2023, approved lecanemab, a drug that targets the basic pathophysiology of Alzheimer’s disease. The FDA action is an “accelerated approval” of the […]